Prolium Bioscience, founded in 2025, emerges as a key player in the biotech sector focused on autoimmune diseases. Its slogan, "Depleting Disease, Empowering Health," aptly encapsulates its mission. Specializing in developing innovative therapeutics, the company is advancing its flagship product, PRO-203, which is a potentially best-in-class bispecific CD20xCD3 antibody targeting serious conditions like systemic sclerosis (SSc) and systemic lupus erythematosus (SLE).
Backed by RTW Investments, Prolium Bioscience boasts a skilled team with substantial expertise in autoimmune therapeutics. While specific investment amounts remain undisclosed, the company's strong foundation suggests it is well-positioned to attract future investment for its promising therapies. Investors may find substantial appeal in the high unmet medical needs addressed by Prolium's research, aligning with trends toward targeted, efficacious treatments in the biotech industry.
